Device Trial Radar · NCT05621876
Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia
Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
May 15, 2024
Primary completion
Sep 1, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- PATHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; Institut Pasteur de Tunis; Centre National de Greffe de Moelle Osseuse
- First posted
- Nov 18, 2022
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 6 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the usability and utility of the device, % agreement between the PID-RDT and the referent assay (serum/plasma), and % agreement between capillary blood and venous blood samples using the PID-RDT within confirmed PID patients prior to receipt of their monthly IV-Ig treatment.
Conditions
- Primary Immunodeficiency Diseases
Interventions
IgG deficiency rapid screening testDevice
We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluateusability among end users of the PID rapid screening tests using capillary blood samples obtained from PID patients, prior to receipt of IV-Ig treatment.Time frame: 3 month
- To evaluate % agreement between the PID RDT(using capillary blood)and the referent test (serum/plasma).Time frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Bone Marrow Transplant center
Tunis, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.